Novel Developments on Skin Cancer Diagnostics and Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 10 August 2024 | Viewed by 6378
Special Issue Editor
2. Fleur Hiege Center für Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany
Interests: immuno-oncology; melanoma; cutaneous squamous cell carcinoma; uveal melanoma; liquid biopsy; circulating tumor-derived DNA; molecular diagnostics; gene expression profiling; proteomics; damage-associated molecular pattern; innate immunity; tumor micro-environment
Special Issue Information
Dear Colleagues,
Skin cancer treatment has advanced tremendously with novel immunotherapies and targeted therapies significantly improving patients' survival. Most interestingly, skin cancers, such as melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma and others, share a similar pathogenesis as exposure to sunlight is considered the main risk factor for genetic mutations and the subsequent malignant transformation. Nevertheless, there is still a relatively high risk for treatment resistance and severe treatment-related side effects. In order to identify patients at risk, to select the best treatment regime and sequence, and to predict treatment-related toxicity, molecular diagnostics are needed based on a deep understanding of the complex underlying mechanisms. In this Special Issue, we will publish original research articles and reviews providing new insights into skin cancer diagnostics and treatment.
We look forward to receiving your contributions.
Prof. Dr. Christoffer Gebhardt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- cutaneous squamous cell carcinoma
- uveal melanoma
- basal cell carcinoma
- Merkel cell carcinoma
- liquid biopsy
- molecular diagnostics
- immune checkpoint inhibition
- immune cell subsets
- treatment resistance